AZD-1656 is primarily researched for its potential therapeutic applications in the treatment of type 1 and type 2 diabetes. It functions as a glucokinase activator, which helps regulate blood glucose levels by enhancing the activity of the glucokinase enzyme. This enzyme plays a critical role in glucose metabolism, particularly in the liver and pancreas. By activating glucokinase, AZD-1656 promotes insulin secretion and improves glucose uptake, making it a promising candidate for managing diabetes. Additionally, its mechanism of action may offer benefits in reducing the risk of diabetes-related complications, such as cardiovascular issues. Research is ongoing to evaluate its efficacy, safety, and potential for long-term use in diabetic patients.